An Intensive Treatment Unit doctor said Brian's prognosis was poor and he died surrounded by his family at 9.45pm on June 29.

Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

19, 2025 — People with pockets of fat hidden inside their muscles are at a higher risk of dying or being hospitalized from a heart attack or heart failure ... oxygen treatment as a potential ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Female patients who deliver twins vs singletons are more apt to return to the hospital for CVD, especially during the first ...

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti ...

According to ADHERE (Acute Decompensated Heart Failure National Registry), 47% of the patients admitted to the hospital ... In the following sections, diagnostic and treatment strategies for specific ...

Heart failure is a pathological condition in which the heart is unable to pump enough blood to the rest of the body, because it is either unable to fill with a sufficient volume of blood or unable ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Over the past decades, great efforts have been made to overcome treatment failure, including identification of biomarkers, exploration of the reasons for loss of efficacy, development of sequential or ...

Transparency Notifications from Shareholders Ghent, Belgium - 3 February 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of ...

SARS-CoV-2 infection was associated with more rapid coronary plaque progression and significantly increased risk for adverse ...